Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ophthalmic specialty firm Novagali Pharma has announced the commercial launch in France of its first product Cationorm, a cationic emulsion to treat dry eye symptoms.
Subscribe to our email newsletter
The commercial launch of Cationorm in Europe and in the US by the end 2008, where the product complies with the over-the-counter status, is said to be a major event for the development of Novagali Pharma.
Cationorm uniquely combines lubricating and hydrating properties, optimal spreading on the surface of the eye, replenishment of the tear film lipid layer and prevention of tear evaporation. The results of clinical study have clearly demonstrated Cationorm advantages for patients: tolerance, long-lasting relief and optimal comfort.
Jerome Martinez, CEO of Novagali Pharma, said: “Cationorm commercial launch is very special to us being our first marketed product coming out of our pipeline. It is the result of many years of work for the entire Novagali team and we are very proud of the innovation Cationorm brings for the treatment of dry eye symptoms.”